WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2012109280) APOE IMMUNOTHERAPY
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2012/109280    International Application No.:    PCT/US2012/024195
Publication Date: 16.08.2012 International Filing Date: 07.02.2012
IPC:
C12P 21/08 (2006.01), A61K 39/395 (2006.01), G01N 33/00 (2006.01)
Applicants: NEOTOPE BIOSCIENCES LIMITED [IE/IE]; Treasury Building Lower Grand Canal Street 2 Dublin (IE) (For All Designated States Except US).
SCHENK, Dale, B. [US/US]; (US) (For US Only).
NIJJAR, Tarlochan, S. [US/US]; (US) (For US Only).
PAYNE, Philip, W. [US/US]; (US) (For US Only).
BARBOUR, Robin [US/US]; (US) (For US Only)
Inventors: SCHENK, Dale, B.; (US).
NIJJAR, Tarlochan, S.; (US).
PAYNE, Philip, W.; (US).
BARBOUR, Robin; (US)
Agent: CHEN, ShengFeng; Alston & Bird LLP Bank of America Plaza 101 South Tryon Street Suite 4000 Charlotte, NC 28280-4000 (US)
Priority Data:
61/440,284 07.02.2011 US
Title (EN) APOE IMMUNOTHERAPY
(FR) IMMUNOTHÉRAPIE PAR L'INTERMÉDIAIRE D'APOE
Abstract: front page image
(EN)The disclosure provides antibodies that preferentially bind to an ApoE(1-272) fragment relative to ApoE(1-299). Further disclosed are humanized monoclonal antibody comprising three light chain Kabat CDRs and three heavy chain Kabat CDRs with framwork modifications. These antibodies serve to reduce the toxicity of this fragment and find use in treatment and prophylaxis of a variety of neurological diseases.
(FR)La présente invention concerne des anticorps qui se lient préférentiellement à un fragment ApoE(1-272) par rapport à ApoE(1-299). Ces anticorps servent à réduire la toxicité de ce fragment et ont une utilité dans le traitement et la prophylaxie d'une variété de maladies neurologiques.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)